{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:00:29Z","timestamp":1793152829159,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Medical Sciences"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.advms.2022.10.001","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T03:22:13Z","timestamp":1667359333000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between Mpro and antiviral drugs (nirmatrelvir and ritonavir)"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8988-5957","authenticated-orcid":false,"given":"Ali Adel","family":"Dawood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.advms.2022.10.001_bib1","doi-asserted-by":"crossref","first-page":"802","DOI":"10.2174\/1389450122666210906154849","article-title":"Exploring the SARS-cov-2 main protease (Mpro) and RdRp targets by updating current structure-based drug design utilizing Co-crystals to combat COVID-19","volume":"23","author":"Tarannum","year":"2022","journal-title":"Curr Drug Targets"},{"issue":"15","key":"10.1016\/j.advms.2022.10.001_bib2","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2174\/1568026621666210727162324","article-title":"Exploring the COVID-19 potential targets: big challenges to quest specific treatment","volume":"21","author":"Roy","year":"2021","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.advms.2022.10.001_bib3","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s12985-020-01457-0","article-title":"Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2\u2032s main protease","volume":"17","author":"Mahdi","year":"2020","journal-title":"Virol J"},{"issue":"3","key":"10.1016\/j.advms.2022.10.001_bib4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.15789\/1563-0625-IOS-2486","article-title":"Influence of SARS-CoV-2 variants' spike glycoprotein and RNA-dependent RNA polymerase (Nsp12) mutations on remdesivir docking residues","volume":"24","author":"Dawood","year":"2022","journal-title":"Med Immuno Rus"},{"key":"10.1016\/j.advms.2022.10.001_bib5","first-page":"FSO640","article-title":"Exploring the effect of ritonavir and TMC-310911 on SARS-CoV-2 and SARS-CoV main proteases: potential from a molecular perspective","author":"Soremekun","year":"2020","journal-title":"Fut Sci OA"},{"issue":"2","key":"10.1016\/j.advms.2022.10.001_bib6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41589-020-00689-z","article-title":"SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging","volume":"17","author":"Rut","year":"2021","journal-title":"Nat Chem Biol"},{"issue":"7","key":"10.1016\/j.advms.2022.10.001_bib7","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2174\/1386207323999200824115536","article-title":"The antiviral and antimalarial drug repurposing in quest of chemotherapeutics to combat COVID-19 utilizing structure-based molecular docking","volume":"24","author":"Nandi","year":"2021","journal-title":"Comb Chem High Throughput Screen"},{"key":"10.1016\/j.advms.2022.10.001_bib8","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2174\/1570180818666211007111105","article-title":"Repurposing of drugs and HTS to combat SARS-CoV-2 main protease utilizing structure-based molecular docking","volume":"19","author":"Nandi","year":"2022","journal-title":"Lett Drug Des Discov"},{"key":"10.1016\/j.advms.2022.10.001_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2022.105400","article-title":"Increasing the frequency of omicron variant mutations boosts the immune response and may reduce the virus virulence","volume":"164","author":"Dawood","year":"2022","journal-title":"Microb Pathog"},{"key":"10.1016\/j.advms.2022.10.001_bib10","article-title":"Structural basis of potential inhibitors targeting SARS-CoV-2 main protease","volume":"9","author":"Mengist","year":"2021","journal-title":"Frontiers"},{"issue":"7898","key":"10.1016\/j.advms.2022.10.001_bib11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.advms.2022.10.001_bib12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.advms.2022.10.001_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jim.2011.02.004","article-title":"Validation of assays to monitor immune responses in the Syrian golden hamster (Mesocricetus auratus)","volume":"368","author":"Zivcec","year":"2011","journal-title":"J\u00a0Immunol Methods"},{"issue":"2","key":"10.1016\/j.advms.2022.10.001_bib14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.15407\/microbiolj83.02.082","article-title":"Molecular docking of SARS-CoV-2 nucleocapsid protein with angiotensin-converting enzyme II","volume":"83","author":"Dawood","year":"2021","journal-title":"Mikrobio Zhu"},{"issue":"7","key":"10.1016\/j.advms.2022.10.001_bib15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat Rev Microbiol"},{"issue":"2","key":"10.1016\/j.advms.2022.10.001_bib16","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/vaccines8020153","article-title":"Progress and prospects on vaccine development against SARS-CoV-2","volume":"8","author":"Zhang","year":"2020","journal-title":"Vaccines"},{"issue":"4","key":"10.1016\/j.advms.2022.10.001_bib17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.15789\/1563-0625-IOS-2455","article-title":"Identification of Surface glycoprotein mutations of SARS-CoV-2 in isolated strains from Iraq","volume":"24","author":"Dawood","year":"2022","journal-title":"Med Immuno Rus"},{"issue":"7","key":"10.1016\/j.advms.2022.10.001_bib18","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.chom.2021.06.016","article-title":"The success of SARS-CoV-2 vaccines and challenges ahead","volume":"29","author":"Subbarao","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"6489","key":"10.1016\/j.advms.2022.10.001_bib19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.advms.2022.10.001_bib20","series-title":"Discovery studio visualizer 2021 client","author":"Benedict","year":"2021"},{"issue":"8","key":"10.1016\/j.advms.2022.10.001_bib21","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1021\/acs.jcim.1c00203","article-title":"AutoDock Vina 1.2.0: new docking methods, expanded force field, and Python bindings","volume":"61","author":"Eberhardt","year":"2021","journal-title":"J\u00a0Chem Inf Model"},{"issue":"W1","key":"10.1016\/j.advms.2022.10.001_bib22","doi-asserted-by":"crossref","first-page":"W542","DOI":"10.1093\/nar\/gkw340","article-title":"InterEvDock: a docking server to predict the structure of protein-protein interactions using evolutionary information","volume":"44","author":"Vavrusa","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.advms.2022.10.001_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.716466","article-title":"SeamDock: an interactive and collaborative online docking resource to assist small compound molecular docking","volume":"8","author":"Murail","year":"2021","journal-title":"Front Mol Biosci"},{"issue":"5","key":"10.1016\/j.advms.2022.10.001_bib24","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"Genheden","year":"2015","journal-title":"Expet Opin Drug Discov"},{"issue":"17","key":"10.1016\/j.advms.2022.10.001_bib25","doi-asserted-by":"crossref","first-page":"7772","DOI":"10.1021\/ja00070a024","article-title":"Quantitative J correlation: a new approach for measuring homonuclear three-bond J (HNH.alpha.) coupling constants in 15N-enriched proteins","volume":"115","author":"Vuister","year":"1993","journal-title":"J\u00a0Am Chem Soc"},{"issue":"1","key":"10.1016\/j.advms.2022.10.001_bib26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: visual molecular dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J\u00a0Mol Graph"},{"key":"10.1016\/j.advms.2022.10.001_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128629","article-title":"Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir","author":"Ullrich","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"10.1016\/j.advms.2022.10.001_bib28","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","article-title":"The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic","volume":"185","author":"Hoffmann","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.advms.2022.10.001_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.coviro.2021.06.003","article-title":"Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19","volume":"50","author":"Painter","year":"2021","journal-title":"Curr Opin Virol"},{"issue":"7","key":"10.1016\/j.advms.2022.10.001_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101941","article-title":"Dynamically-driven enhancement of the catalytic machinery of the SARS 3C-like protease by the S284-T285-I286\/A mutations on the extra domain","volume":"9","author":"Lim","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.advms.2022.10.001_bib31","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1742-4658.2006.05130.x","article-title":"The catalysis of the SARS 3C-like protease is under extensive regulation by its extra domain","volume":"273","author":"Shi","year":"2006","journal-title":"FEBS J"},{"issue":"7","key":"10.1016\/j.advms.2022.10.001_bib32","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.bpj.2009.12.4272","article-title":"Mutation of Glu-166 blocks the substrate-induced dimerization of SARS coronavirus main protease","volume":"98","author":"Cheng","year":"2010","journal-title":"Biophys J"},{"issue":"4","key":"10.1016\/j.advms.2022.10.001_bib33","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/13543776.2021.1884224","article-title":"Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents","volume":"31","author":"Spratt","year":"2021","journal-title":"Expert Opin Ther Pat"},{"issue":"6575","key":"10.1016\/j.advms.2022.10.001_bib34","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.advms.2022.10.001_bib35","article-title":"Oral administration of S-217622, a SARS-CoV-2 main protease inhibitor, decreases 1 viral load and accelerates recovery from clinical aspects of COVID-19","author":"Sasaki","year":"2022","journal-title":"bioRxiv"}],"container-title":["Advances in Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112622000402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1896112622000402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:43:02Z","timestamp":1761824582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1896112622000402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1896112622000402"],"URL":"https:\/\/doi.org\/10.1016\/j.advms.2022.10.001","relation":{},"ISSN":["1896-1126"],"issn-type":[{"value":"1896-1126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between Mpro and antiviral drugs (nirmatrelvir and ritonavir)","name":"articletitle","label":"Article Title"},{"value":"Advances in Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.advms.2022.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}